James Sapirstein, Chairman, President & CEO of First Wave BioPharma, Inc. FWBI recently shared insights on Benzinga’s All-Access. First Wave BioPharma is dedicated to pioneering non-systemic therapies for gastrointestinal (GI) diseases. The company is pursuing research on numerous revolutionary therapies for GI diseases. You can watch the full interview here. Featured photo by Hans Reniers ...
On CNBC’s “Halftime Report Final Trades,” Liz Young of BNY Mellon Investment Management highlighted the Health Care Select Sector SPDR Fund XLV as her final trade. Joshua Brown of Ritholtz Wealth Management selected Pfizer Inc. PFE, which bottomed in the middle of December. At the JPMorgan Healthcare Conference, Pfizer CEO Albert Bourla expressed the company’s ...
Market Momentum and Stock Performance Amid a surge in market activity, numerous stocks are approaching or surpassing their 52-week highs. Among the standout performers are household names such as Amazon, Arista Networks, and Abercrombie & Fitch. These companies not only exhibit strong momentum but also hold favorable Zacks Ranks, indicative of upward revisions in earnings ...
A recent surge of over 9 options trades for Beyond Meat BYND is heightening investor interest. The total value of these trades reaches a notable $459,745. Another 7 transactions further swirl the waters with a total of $442,745. These developments are ushering in a fresh wave of speculation on Wall Street. Assessing the Price Target ...
KLA Corporation KLAC is all set to disclose its second-quarter fiscal 2024 results on Jan 25. For the fiscal second quarter, KLAC expects revenues in the range of $2.45 billion, plus/minus $125 million. The Zacks Consensus Estimate for revenues is at $2.46 billion, indicating a decline of 17.72% from the year-ago fiscal quarter’s reported figure. ...
When a stock skyrockets, it’s natural to wonder if it’s still a worthy buy. While it might seem like such momentum can’t last forever, overlooking stocks that have shown immense growth could mean missing out on a lucrative investment opportunity. Every market winner deserves a case-by-case analysis before deciding to buy, sell, hold, or avoid. ...
Right now marks an exciting moment for CRISPR Therapeutics (NASDAQ: CRSP) and its investors. The biotech company has reached three milestones in just a couple of months. First, back in November, the U.K. authorized Casgevy for sickle cell disease and beta thalassemia, the world’s first regulatory nod for a CRISPR gene editing-based therapeutic. Then, in ...
Advanced Micro Devices (AMD) Source: JHVEPhoto / Shutterstock.com Advanced Micro Devices (AMD) is well-positioned to challenge its competitors and make a name in the AI chip race in 2024, following the announcement of its MI300x GPU chipset. This move represents a significant step for the chipmaker and could potentially set the stage for a super ...
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Friday. The Dow traded up 0.95% to 37,824.10 while the NASDAQ rose 1.39% to 15,264.30. The S&P 500 also rose, gaining, 1.06% to 4,831.75. Market Movers Information technology shares rose by 1.6% on Friday. In ...
Tempur Sealy International Inc TPX is moving forward to finalize the Mattress Firm acquisition this year. The Lexington, Kentucky-based company has emerged as a “dominant” player in the mattress industry and its multi-year growth outlook is “becoming highly attractive to long-term investors,” according to Piper Sandler. The Tempur Sealy International Analyst: Peter Keith upgraded the ...
